Q2 FY26 profit rises 26%; H1 profit rises 33%

Ebitda Margin ExpansionPat Growth 25pctEmphasis Of MatterResults View source PDF Explain this filing

APOLLOHOSP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.8%Reaction day

₹7783.00

prior close

₹7789.00

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)-0.0%-1.8% vs market

Hospital peers, median of 20sector+0.2%-2.0% vs sector

On the reaction day the stock moved 1.8 pts less than Nifty 100 and 2.0 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

-0.5

15m

-0.5

30m

-1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.8-0.0-1.8+0.2-2.0

Next day

-3.2+0.3-3.5-1.2-2.0

-3.4+0.7-4.1-1.9-1.5

-3.6+1.3-4.9-1.7-1.9

-4.4+1.3-5.7-2.2-2.2

-4.7+1.4-6.1-2.4-2.3

-5.2+1.4-6.6-2.0-3.2

15d

-5.7+2.2-8.0-2.7-3.0

-8.8+1.0-9.8-5.1-3.7

-4.2+2.4-6.6-7.2+3.1

-7.2+1.3-8.5-11.8+4.6

UpDownMarket · Nifty 100Sector · Hospital peers, median of 20Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY26 consolidated revenue rose 13% to Rs 6,304 crore and EBITDA rose 15% to Rs 941 crore. Profit after tax rose 26% to Rs 477 crore; earnings per share was Rs 33.19. In H1, revenue grew 14% to Rs 12,146 crore, EBITDA 20% to Rs 1,793 crore and profit after tax 33% to Rs 910 crore. Deloitte flagged a subsidiary land dispute; its conclusion was unchanged. Competition Commission approved the pharmacy and digital health demerger.

Likely market impact

Profit growth and EBITDA outpacing revenue support positive sentiment. Shareholders will watch demerger execution and the subsidiary land dispute.